<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117448</article-id><article-id pub-id-type="publisher-id">ACM-43892</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_47220280.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  糖皮质激素全身及局部应用治疗小儿毛细支气管炎疗效分析
  An Analysis of Treatment Effect: Systemic and Local Application of Glucocorticoid in Children Bronchiolitis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>明明</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>瑞云</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>艳萍</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛市市立医院，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛；青岛市城阳人民医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff4"><addr-line>青岛市海慈医院，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3091</fpage><lpage>3096</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：观察全身及局部应用糖皮质激素治疗小儿毛细支气管炎的疗效，为临床治疗急性毛细支气管炎提供参考。方法：将155例诊断为毛细支气管炎患儿分成3组，对照组49例，给予化痰、吸氧、补液、抗病毒、抗感染及0.9% NaCl + 博利康尼雾化吸入治疗，治疗I组59例，在对照组基础上加用甲泼尼龙治疗，治疗II组47例，在对照组基础上加用普米克令舒雾化吸入治疗，观察3组临床症状缓解时间及外周血变化情况。结果：治疗I组和治疗II组喘憋缓解时间和住院时间分别为(3.13 &#177; 1.26) d、(10.70 &#177; 1.95) d和(3.13 &#177; 1.00) d、(10.34 &#177; 1.85) d，均短于对照组的(3.83 &#177; 1.22) d、(11.54 &#177; 2.09) d，差异有统计学意义(P &lt; 0.05)；治疗I组发热持续时间(2.07 &#177; 1.59) d短于其他两组(2.95 &#177; 1.88) d、(3.55 &#177; 1.77) d，治疗II组咳嗽持续时间(8.89 &#177; 1.87) d短于其他两组(9.34 &#177; 2.09) d、(9.95 &#177; 2.30) d，差异均有统计学意义(P &lt; 0.05)。治疗7天后，评价疗效，治疗I组、治疗II组和对照组治疗总有效率分别为93.2%、91.5%、87.8%。复查外周血白细胞及血小板，治疗I组血小板计数(511.39 &#177; 140.34) &#215; 10
  <sup>9</sup>/L，明显高于治疗II组(329.91 &#177; 104.49) &#215; 10
  <sup>9</sup>/L和对照组(317.58 &#177; 81.91) &#215; 10
  <sup>9</sup>/L，治疗II组淋巴细胞计数(6.76 &#177; 1.89) &#215; 10
  <sup>9</sup>/L高于治疗I组(5.05 &#177; 2.13) &#215; 10
  <sup>9</sup>/L和对照组(4.77 &#177; 1.86) &#215; 10
  <sup>9</sup>/L，差异均有统计学意义(P &lt; 0.05)。结论：小剂量全身应用甲泼尼龙及局部雾化吸入普米克令舒治疗小儿毛细支气管炎效果好，安全性高，不良反应发生风险较低。
   Objective: Observe the effect of glucocorticoids used by systemic or local in the children suffering from bronchiolitis. Provide a reference for cure bronchiolitis. Methods: 155 cases diagnosed as bronchiolitis were divided into 3 groups. Control group in 49 cases, which was given conventional therapy: such as reduce phlegm, spply oxygen, fluid infusion, antivirus, antibiotics and aerosol inhalation by 0.9% NaCl + salbutamol. Treatment group I in 59 cases, added methyl prednisolone compared with the control group. Treatment group II in 47 cases, added Budesonide compared with the control group. Obseve the changes in clinical symptoms and peripheral blood of children in these 3 groups. Results: Times of asthma remission and hospitaization in treatment group I and treatment group II were (3.13 &#177; 1.26) days, (10.70 &#177; 1.95) days and (3.13 &#177; 1.00) days, (10.34 &#177; 1.85) days, which were shorten than control group’s ((3.83 &#177; 1.22) days, (11.54 &#177; 2.09) days), (P &lt; 0.05). Duration of fever in treatment group I ((2.07 &#177; 1.59) days) was shorter than other groups ((2.95 &#177; 1.88) days, (3.55 &#177; 1.77) days), (P &lt; 0.05). Duration of cough in treatment group II ((8.89 &#177; 1.87) days) was shorter than other groups ((9.34 &#177; 2.09) days, (9.95 &#177; 2.30) days), (P &lt; 0.05). After 7 days of treatment, total effective rate in treatment group I, treatment group II and control group were 93.2%, 91.5%, 87.8%, respectively. Count of platelet in treatment group I ((511.39 &#177; 140.34) &#215; 10
  <sup>9</sup>/L) was more than other groups (treatment group 2 (329.91 &#177; 104.49) &#215; 10
  <sup>9</sup>/L, control group (317.58 &#177; 81.91) &#215; 10
  <sup>9</sup>/L), (P &lt; 0.05). Count of lymphocyte in treatment group II ((6.76 &#177; 1.89) &#215; 10
  <sup>9</sup>/L) was more than other groups (treatment group I (5.05 &#177; 2.13) &#215; 10
  <sup>9</sup>/L, control group (4.77 &#177; 1.86) &#215; 10
  <sup>9</sup>/L), (P &lt; 0.05). Conclusion: Small doses of methyl prednisolone and atomization inhalation have good effects, high safety and low risk.
 
</p></abstract><kwd-group><kwd>毛细支气管炎，甲泼尼龙，布地奈德, Bronchiolitis</kwd><kwd> Methyl Prednisolone</kwd><kwd> Budesonide</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：观察全身及局部应用糖皮质激素治疗小儿毛细支气管炎的疗效，为临床治疗急性毛细支气管炎提供参考。方法：将155例诊断为毛细支气管炎患儿分成3组，对照组49例，给予化痰、吸氧、补液、抗病毒、抗感染及0.9% NaCl + 博利康尼雾化吸入治疗，治疗I组59例，在对照组基础上加用甲泼尼龙治疗，治疗II组47例，在对照组基础上加用普米克令舒雾化吸入治疗，观察3组临床症状缓解时间及外周血变化情况。结果：治疗I组和治疗II组喘憋缓解时间和住院时间分别为(3.13 &#177; 1.26) d、(10.70 &#177; 1.95) d和(3.13 &#177; 1.00) d、(10.34 &#177; 1.85) d，均短于对照组的(3.83 &#177; 1.22) d、(11.54 &#177; 2.09) d，差异有统计学意义(P &lt; 0.05)；治疗I组发热持续时间(2.07 &#177; 1.59) d短于其他两组(2.95 &#177; 1.88) d、(3.55 &#177; 1.77) d，治疗II组咳嗽持续时间(8.89 &#177; 1.87) d短于其他两组(9.34 &#177; 2.09) d、(9.95 &#177; 2.30) d，差异均有统计学意义(P &lt; 0.05)。治疗7天后，评价疗效，治疗I组、治疗II组和对照组治疗总有效率分别为93.2%、91.5%、87.8%。复查外周血白细胞及血小板，治疗I组血小板计数(511.39 &#177; 140.34) &#215; 10<sup>9</sup>/L，明显高于治疗II组(329.91 &#177; 104.49) &#215; 10<sup>9</sup>/L和对照组(317.58 &#177; 81.91) &#215; 10<sup>9</sup>/L，治疗II组淋巴细胞计数(6.76 &#177; 1.89) &#215; 10<sup>9</sup>/L高于治疗I组(5.05 &#177; 2.13) &#215; 10<sup>9</sup>/L和对照组(4.77 &#177; 1.86) &#215; 10<sup>9</sup>/L，差异均有统计学意义(P &lt; 0.05)。结论：小剂量全身应用甲泼尼龙及局部雾化吸入普米克令舒治疗小儿毛细支气管炎效果好，安全性高，不良反应发生风险较低。</p></sec><sec id="s2"><title>关键词</title><p>毛细支气管炎，甲泼尼龙，布地奈德</p></sec><sec id="s3"><title>An Analysis of Treatment Effect: Systemic and Local Application of Glucocorticoid in Children Bronchiolitis<sup> </sup></title><p>Mingming Sun<sup>1,2*</sup>, Ruiyun Zhang<sup>3#</sup>, Yanping Wang<sup>4</sup><sup>†</sup></p><p><sup>1</sup>Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Chengyang People’s Hospital, Qingdao Shandong</p><p><sup>3</sup>Qingdao Municipal Hospital, Qingdao Shandong</p><p><sup>4</sup>Qingdao Hiser Hospital, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/29-1572360x5_hanspub.png?20210716082943846" /></p><p>Received: Jun. 12<sup>th</sup>, 2021; accepted: Jul. 1<sup>st</sup>, 2021; published: Jul. 15<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/29-1572360x6_hanspub.png?20210716082943846" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: Observe the effect of glucocorticoids used by systemic or local in the children suffering from bronchiolitis. Provide a reference for cure bronchiolitis. Methods: 155 cases diagnosed as bronchiolitis were divided into 3 groups. Control group in 49 cases, which was given conventional therapy: such as reduce phlegm, spply oxygen, fluid infusion, antivirus, antibiotics and aerosol inhalation by 0.9% NaCl + salbutamol. Treatment group I in 59 cases, added methyl prednisolone compared with the control group. Treatment group II in 47 cases, added Budesonide compared with the control group. Obseve the changes in clinical symptoms and peripheral blood of children in these 3 groups. Results: Times of asthma remission and hospitaization in treatment group I and treatment group II were (3.13 &#177; 1.26) days, (10.70 &#177; 1.95) days and (3.13 &#177; 1.00) days, (10.34 &#177; 1.85) days, which were shorten than control group’s ((3.83 &#177; 1.22) days, (11.54 &#177; 2.09) days), (P &lt; 0.05). Duration of fever in treatment group I ((2.07 &#177; 1.59) days) was shorter than other groups ((2.95 &#177; 1.88) days, (3.55 &#177; 1.77) days), (P &lt; 0.05). Duration of cough in treatment group II ((8.89 &#177; 1.87) days) was shorter than other groups ((9.34 &#177; 2.09) days, (9.95 &#177; 2.30) days), (P &lt; 0.05). After 7 days of treatment, total effective rate in treatment group I, treatment group II and control group were 93.2%, 91.5%, 87.8%, respectively. Count of platelet in treatment group I ((511.39 &#177; 140.34) &#215; 10<sup>9</sup>/L) was more than other groups (treatment group 2 (329.91 &#177; 104.49) &#215; 10<sup>9</sup>/L, control group (317.58 &#177; 81.91) &#215; 10<sup>9</sup>/L), (P &lt; 0.05). Count of lymphocyte in treatment group II ((6.76 &#177; 1.89) &#215; 10<sup>9</sup>/L) was more than other groups (treatment group I (5.05 &#177; 2.13) &#215; 10<sup>9</sup>/L, control group (4.77 &#177; 1.86) &#215; 10<sup>9</sup>/L), (P &lt; 0.05). Conclusion: Small doses of methyl prednisolone and atomization inhalation have good effects, high safety and low risk.</p><p>Keywords:Bronchiolitis, Methyl Prednisolone, Budesonide</p><disp-formula id="hanspub.43892-formula14"><graphic xlink:href="//html.hanspub.org/file/29-1572360x7_hanspub.png?20210716082943846"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/29-1572360x8_hanspub.png?20210716082943846" /> <img src="//html.hanspub.org/file/29-1572360x9_hanspub.png?20210716082943846" /></p></sec><sec id="s5"><title>1. 引言</title><p>毛细支气管炎(bronchiolitis)是一种婴幼儿较常见的下呼吸道感染，多见于2岁以下婴幼儿，最常见的病原是呼吸道合胞病毒(RSV)，其次是副流感病毒、腺病毒、流感病毒等，少数由肺炎支原体引起。咳与喘憋同时发生为本病特点，本病无特效治疗。糖皮质激素作为一种类固醇激素，不但有较好的抗炎作用，而且能够舒张支气管平滑肌，同时还参与免疫调节，目前被广泛应用于喘息性疾病的治疗中 [<xref ref-type="bibr" rid="hanspub.43892-ref1">1</xref>]。但长期全身应用糖皮质激素副作用较大，治疗毛细支气管炎是否全身应用糖皮质激素仍存在争议。本文研究对象为2015年1月~2016年3月在我院住院的毛细支气管炎患儿，常规治疗组为对照组，研究组在常规治疗的基础上分别给与甲泼尼龙琥拍酸钠静脉滴注、布地奈德混悬液氧气驱动雾化吸入两种不同糖皮质激素的给与方式，分别为治疗I组(甲泼尼龙组)和治疗II组(普米克令舒组)。对三组患儿治疗疗效进行分析，探讨三组治疗对咳嗽、喘憋缓解时间、肺部哮鸣音湿啰音消失时间及住院天数的影响，并对治疗5~7天后白细胞及血小板变化规律作一探讨，进一步观察糖皮质激素治疗毛细支气管炎对外周血象的影响。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>研究对象为2015年1月~2016年3月在青岛市市立医院住院的毛细支气管炎患儿155例，年龄 &lt; 2岁。其中治疗I组59例，男22例，女37例；年龄1.27~20.00个月，平均年龄(7.32 &#177; 5.76)个月；病程7.00~14.00 d，平均病程(10.70 &#177; 1.96) d。治疗II组47例，男24例，女23例；年龄0.93~22.00个月，平均年龄(7.29 &#177; 4.58)个月；病程7.00~14.00 d，平均病程(10.34 &#177; 1.85) d；对照组49例，男28例，女21例；年龄1.10~22.00个月，平均年龄(6.58 &#177; 5.28)个月；病程6.00~14.30 d，平均病程(11.55 &#177; 2.02) d。诊断标准参照《诸福棠实用儿科学》 [<xref ref-type="bibr" rid="hanspub.43892-ref2">2</xref>]，排除标准：伴有呼吸衰竭和(或)心力衰竭并发症患儿；治疗前曾使用过茶碱类、糖皮质激素类及支气管扩张类药物治疗的患儿。两组患儿一般资料比较差异无统计学意义(P &gt; 0.05)，具有可比性。</p></sec><sec id="s6_2"><title>2.2. 方法</title><p>所有患儿入院后均给予常规化痰、吸氧、补液等支持治疗，抗病毒药物选用单磷酸阿糖腺苷，对合并细菌感染的患儿给予抗菌药物治疗，所有患儿均给予氧气驱动雾化吸入，每次15~20分钟，每日2次，对照组及治疗I组雾化液为0.9% NaCl 2 ml + 硫酸特布他林雾化液(博利康尼) 1 ml，治疗II组雾化液为吸入用布地奈德混悬液(普米克令舒) 1 mg + 硫酸特布他林雾化液1 ml。治疗I组在常规治疗的基础上给予甲泼尼龙琥珀酸钠1~2 mg/kg∙d静脉滴注，根据病情应用3~5天，治疗7天视为一个疗程。</p></sec><sec id="s6_3"><title>2.3. 疗效判定标准 [<xref ref-type="bibr" rid="hanspub.43892-ref3">3</xref>] <sup> </sup></title><p>患儿治疗7天后评价疗效。痊愈：患儿临床症状体征(发热、咳嗽、喘息、气促等)消失；好转：临床症状体征减轻；无效：患儿临床症状体征无明显缓解，甚至加重。总有效率 = (痊愈例数 + 好转例数)/总例数 &#215; 100%。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>采用SPSS 17.0软件进行数据与资料的分析，计量资料采用均数 &#177; 标准差(x &#177; s)表示，行t检验，计数资料进行χ<sup>2</sup>检验，以p &lt; 0.05为差异具有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 3组患儿病情好转时间及住院时间比较</title><p>治疗后三组患儿在发热时间、喘憋缓解时间、咳嗽消失时间及住院时间之间差异有统计学意义(P &lt; 0.05)。进一步两两比较发现，甲泼尼龙组患儿发热时间较其他两组患儿短，普米克令舒组患儿咳嗽消失时间较其他两组患儿短，甲泼尼龙组与普米克令舒组患儿喘憋缓解时间及住院时间均较对照组短；肺部啰音消失时间在三组患儿中出差异无统计学意义(P = 0.47)，见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The improvement time and hospitalization days were compared of the three groups [n = 155, d, (x &#177; s)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >热程(d)</th><th align="center" valign="middle" >喘憋缓解时间(d)</th><th align="center" valign="middle" >啰音消失时间(d)</th><th align="center" valign="middle" >咳嗽时间(d)</th><th align="center" valign="middle" >住院时间(d)</th></tr></thead><tr><td align="center" valign="middle" >甲泼尼龙组</td><td align="center" valign="middle" >59</td><td align="center" valign="middle" >2.07 &#177; 1.59</td><td align="center" valign="middle" >3.13 &#177; 1.26</td><td align="center" valign="middle" >7.91 &#177; 1.63</td><td align="center" valign="middle" >9.34 &#177; 2.09</td><td align="center" valign="middle" >10.70 &#177; 1.95</td></tr><tr><td align="center" valign="middle" >普米克令舒组</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >2.95 &#177; 1.88</td><td align="center" valign="middle" >3.13 &#177; 1.00</td><td align="center" valign="middle" >7.97 &#177; 2.02</td><td align="center" valign="middle" >8.89 &#177; 1.87</td><td align="center" valign="middle" >10.34 &#177; 1.85</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >3.55 &#177; 1.77</td><td align="center" valign="middle" >3.83 &#177; 1.22</td><td align="center" valign="middle" >8.35 &#177; 2.19</td><td align="center" valign="middle" >9.95 &#177; 2.30</td><td align="center" valign="middle" >11.54 &#177; 2.09</td></tr><tr><td align="center" valign="middle" >F</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >9.79</td><td align="center" valign="middle" >5.97</td><td align="center" valign="middle" >0.77</td><td align="center" valign="middle" >3.05</td><td align="center" valign="middle" >4.77</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >0.47</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >0.01</td></tr></tbody></table></table-wrap><p>表1. 3组患儿病情好转时间及住院天数比较[n = 155, d, (x &#177; s)]</p></sec><sec id="s7_2"><title>3.2. 3组患儿治疗后白细胞及血小板变化情况</title><p>治疗后三组患儿在白细胞计数及中性粒细胞计数之间差异无统计学意义；在淋巴细胞及血小板之间差异有统计学意义(P &lt; 0.05)；进一步两两比较发现，治疗后普米克令舒组患儿淋巴细胞计数高于其余两组患儿，甲泼尼龙组患儿血小板计数高于其余两组患儿，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Changes of leukocytes and platelets in the three groups after treatment (x &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="4"  >白细胞计数 &#215; 10<sup>9</sup>/L)</th><th align="center" valign="middle"  colspan="4"  >中性粒细胞计数 &#215; 10<sup>9</sup>/L</th><th align="center" valign="middle"  colspan="4"  >淋巴细胞计数 &#215; 10<sup>9</sup>/L</th><th align="center" valign="middle"  colspan="4"  >血小板计数 &#215; 10<sup>9</sup>/L</th></tr></thead><tr><td align="center" valign="middle" >最小 值</td><td align="center" valign="middle" >最大值</td><td align="center" valign="middle" >均值 &#177; 标准差</td><td align="center" valign="middle" >均值95% 置信区间</td><td align="center" valign="middle" >最小 值</td><td align="center" valign="middle" >最大值</td><td align="center" valign="middle" >均值 &#177; 标准差</td><td align="center" valign="middle" >均值95% 置信区间</td><td align="center" valign="middle" >最小 值</td><td align="center" valign="middle" >最大 值</td><td align="center" valign="middle" >均值 &#177; 标准差</td><td align="center" valign="middle" >均值95%置信区间</td><td align="center" valign="middle" >最小 值</td><td align="center" valign="middle" >最大值</td><td align="center" valign="middle" >均值 &#177; 标准差</td><td align="center" valign="middle" >均值95% 置信区间</td></tr><tr><td align="center" valign="middle" >甲泼尼 龙组</td><td align="center" valign="middle" >5.13</td><td align="center" valign="middle" >21.23</td><td align="center" valign="middle" >9.02 &#177; 2.58</td><td align="center" valign="middle" >8.29~9.74</td><td align="center" valign="middle" >0.66</td><td align="center" valign="middle" >15.45</td><td align="center" valign="middle" >2.47 &#177; 1.36</td><td align="center" valign="middle" >2.08~2.85</td><td align="center" valign="middle" >3.19</td><td align="center" valign="middle" >17.31</td><td align="center" valign="middle" >5.05 &#177; 2.13</td><td align="center" valign="middle" >4.45~5.65</td><td align="center" valign="middle" >276.00</td><td align="center" valign="middle" >704.00</td><td align="center" valign="middle" >511.39 &#177; 140.34</td><td align="center" valign="middle" >471.90~ 550.86</td></tr><tr><td align="center" valign="middle" >普米克 令舒组</td><td align="center" valign="middle" >3.87</td><td align="center" valign="middle" >14.22</td><td align="center" valign="middle" >8.86 &#177; 2.16</td><td align="center" valign="middle" >8.20~9.51</td><td align="center" valign="middle" >0.69</td><td align="center" valign="middle" >11.20</td><td align="center" valign="middle" >2.62 &#177; 1.75</td><td align="center" valign="middle" >2.09~3.14</td><td align="center" valign="middle" >2.87</td><td align="center" valign="middle" >10.73</td><td align="center" valign="middle" >6.76 &#177; 1.89</td><td align="center" valign="middle" >6.20~7.33</td><td align="center" valign="middle" >53.00</td><td align="center" valign="middle" >543.00</td><td align="center" valign="middle" >329.91 &#177; 104.49</td><td align="center" valign="middle" >298.52~ 361.30</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >3.73</td><td align="center" valign="middle" >14.53</td><td align="center" valign="middle" >8.32 &#177; 2.47</td><td align="center" valign="middle" >7.56~9.06</td><td align="center" valign="middle" >0.88</td><td align="center" valign="middle" >7.54</td><td align="center" valign="middle" >2.61 &#177; 0.85</td><td align="center" valign="middle" >2.36~2.86</td><td align="center" valign="middle" >2.02</td><td align="center" valign="middle" >8.71</td><td align="center" valign="middle" >4.77 &#177; 1.86</td><td align="center" valign="middle" >4.22~5.32</td><td align="center" valign="middle" >21.00</td><td align="center" valign="middle" >521,00</td><td align="center" valign="middle" >317.58 &#177; 81.91</td><td align="center" valign="middle" >293.26~ 341.91</td></tr><tr><td align="center" valign="middle" >F</td><td align="center" valign="middle"  colspan="4"  >1.07</td><td align="center" valign="middle"  colspan="4"  >0.19</td><td align="center" valign="middle"  colspan="4"  >13.81</td><td align="center" valign="middle"  colspan="4"  >45.43</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle"  colspan="4"  >0.35</td><td align="center" valign="middle"  colspan="4"  >0.83</td><td align="center" valign="middle"  colspan="4"  >&lt;0.01</td><td align="center" valign="middle"  colspan="4"  >&lt;0.01</td></tr></tbody></table></table-wrap><p>表2. 3组患儿治疗后白细胞及血小板变化情况(x &#177; s)</p></sec><sec id="s7_3"><title>3.3. 3组患儿临床治疗效果比较</title><p>甲泼尼龙组患儿痊愈45例，好转10例，未愈4例，总有效率93.2%；普米克令舒组患儿痊愈36例，好转7例，未愈4例，总有效率91.5%；对照组患儿痊愈36例，好转7例，未愈6例，总有效率87.8%。研究组患儿治疗总有效率高于对照组患儿，见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of treatment effect among 3 groups [n (%)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >痊愈人数</th><th align="center" valign="middle" >好转人数</th><th align="center" valign="middle" >未愈人数</th><th align="center" valign="middle" >总有效率/%</th></tr></thead><tr><td align="center" valign="middle" >甲泼尼组</td><td align="center" valign="middle" >59</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >93.2%</td></tr><tr><td align="center" valign="middle" >普米克令舒组</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >91.5%</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >87.8%</td></tr></tbody></table></table-wrap><p>表3. 3组患儿治疗效果比较[n (%)]</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>毛细支气管炎主要由病毒感染引起。病变主要侵及直径75~300 μm的毛细支气管，黏液分泌增加，有细胞破坏物、纤维素堵塞，出现上皮细胞坏死及支气管周围淋巴细胞浸润，引起气道部分或完全阻塞，阻塞区域远段可出现肺不张、肺气肿等，进而可导致肺通气和肺换气失调产生低氧血症 [<xref ref-type="bibr" rid="hanspub.43892-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.43892-ref5">5</xref>]。糖皮质激素通过与靶细胞浆内的糖皮质激素受体相结合，影响参与炎症的基因转录，从而产生抗炎效应。糖皮质激素可抑制多种炎症细胞如嗜酸性粒细胞、中性粒细胞、单核巨噬细胞和肥大细胞等的趋化、游走、聚集和分泌，具有较强的抗炎作用。治疗量的糖皮质激素还有抗过敏、调节免疫等作用，能够增强血管张力，减轻充血和降低毛细血管通透性，对于喘息性支气管炎症的患儿效果明显且迅速 [<xref ref-type="bibr" rid="hanspub.43892-ref6">6</xref>]。本研究发现，全身应用糖皮质激素(甲泼尼龙琥珀酸钠)与局部雾化吸入糖皮质激素(普米克令舒)均能缩短患儿喘憋缓解的时间及住院时间，这与Teeratakulpisarn等 [<xref ref-type="bibr" rid="hanspub.43892-ref7">7</xref>] 的研究一致。本研究还发现，全身小剂量应用甲泼尼龙，患儿发热时间明显缩短，考虑这与糖皮质激素的免疫抑制机制有关。另外，本研究发现，局部应用普米克令舒雾化吸入组患儿的咳嗽时间较其他两组患儿缩短。普米克令舒的主要成分为布地奈德，是一种吸入性的糖皮质激素，有研究认为，普米克令舒与糖皮质激素的受体有较强的亲和力，同时，普米克令舒的水溶性比较好，可以在凝胶层中保持有效的血药浓度，也能够与水样层中的黏膜组织结合，延长普米克令舒药物在支气管中滞留的时间，使得其抗炎以及抑制变态反应的强度相当于氢可化的松的600倍，相当于地塞米松的30倍，起效时间快，使用剂量小，有利于彻底消除患者气道的炎症反应 [<xref ref-type="bibr" rid="hanspub.43892-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.43892-ref9">9</xref>]。本研究结果显示，全身应用甲泼尼龙与吸入普米克令舒治疗的患儿，治疗后的总有效率分别为93.2和91.5%，明显高于常规药物治疗的患儿87.8%的总有效率，这与蒋红宇 [<xref ref-type="bibr" rid="hanspub.43892-ref10">10</xref>] 等的研究一致。糖皮质激素可抑制白细胞向循环池外移行，抑制溶酶体蛋白水解酶释放，致使外周血白细胞数及中性粒细胞数暂时性增高，抑制淋巴细胞增殖及激活，可降低外周血淋巴细胞数，能刺激骨髓造血功能，使血液中红细胞、血小板、多核白细胞数增加。本研究结果发现，治疗后白细胞及中性粒细胞在三组患儿之间的差异无统计学意义，普米克令舒组患儿淋巴细胞计数高于其他两组患儿，甲泼尼龙组患儿血小板计数高于其他两组患儿。治疗后白细胞、中性粒细胞及淋巴细胞的变化与以往研究不一致，考虑与样本数量较少有关，下一步将会增加样本量，做进一步探讨。目前认为短期小剂量应用糖皮质激素对患儿外周血象影响不大。</p><p>综上所述，小剂量应用甲泼尼龙及雾化吸入普米克令舒治疗小儿毛细支气管炎效果好，能有效缓解患儿喘憋症状，缩短住院时间，安全性高，不良反应发生风险较低，值得临床推广应用。</p></sec><sec id="s9"><title>声明</title><p>该实验已获得患者家属的知情同意及医院伦理委员会批准。</p></sec><sec id="s10"><title>文章引用</title><p>孙明明,张瑞云,王艳萍. 糖皮质激素全身及局部应用治疗小儿毛细支气管炎疗效分析An Analysis of Treatment Effect: Systemic and Local Application of Glucocorticoid in Children Bronchiolitis[J]. 临床医学进展, 2021, 11(07): 3091-3096. https://doi.org/10.12677/ACM.2021.117448</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43892-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">姚丽霞. 布地奈德雾化吸入治疗老年哮喘的疗效及其对血清白细胞介素-2、白细胞介素-5和γ-干扰素水平的影响[J]. 新乡医学院学报, 2016, 33(1): 61-63.</mixed-citation></ref><ref id="hanspub.43892-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">胡亚美, 江载芳, 申昆玲, 等. 诸福棠实用儿科学上册[M]. 第八版. 北京: 人民卫生出版社, 2015: 1276-1277.</mixed-citation></ref><ref id="hanspub.43892-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">刘晓玲, 査梅宝, 陈梅俐, 等. 布地奈德联合沙丁胺醇雾化吸入治疗毛细支气管炎疗效观察[J]. 儿科药学杂志, 2017, 23(3): 27-29.</mixed-citation></ref><ref id="hanspub.43892-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Zorc, J.J. and Hall, C.B. (2010) Bronchiolitis: Recent Evidence on Diagnosis and Managemen. Pediatrics, 125, 342-345.  
&lt;br&gt;https://doi.org/10.1542/peds.2009-2092</mixed-citation></ref><ref id="hanspub.43892-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Sheeran, P., Jafri, H., Carubelli, C., et al. (1999) Elevated Cytokine Concentrations in the Nasopharyngeal and Tracheal Secretions of Children with Respiratory Syncytial Virus Disease. The Pediatric Infectious Disease Journal, 18, 115-122. &lt;br&gt;https://doi.org/10.1097/00006454-199902000-00007</mixed-citation></ref><ref id="hanspub.43892-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">杨宝峰, 苏定冯, 李智, 等. 药理学[M]. 第六版. 北京: 人民卫生出版社, 2003: 361-368.</mixed-citation></ref><ref id="hanspub.43892-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Teeratakulpisarn, J., Limwattananon, C., Tanupattarachai, S., et al. (2007) Efficacy of Dexamethasone Injection for Acute Bronchiolitis in Hospitalized Children: A Randomized, Double-Blind, Placebo-Controlled Trial. Pediatric Pulmonology, 42, 433-439. &lt;br&gt;https://doi.org/10.1002/ppul.20585</mixed-citation></ref><ref id="hanspub.43892-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">严建佳, 钟秋兰, 郑亚文, 等. 氧驱动雾化吸入与空气压缩泵雾化吸入治疗小儿哮喘的效果[J]. 临床医学, 2016, 36(8): 103-105.</mixed-citation></ref><ref id="hanspub.43892-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">马莉. 氧驱雾化吸入普米克令舒治疗小儿哮喘急性发作疗效及对肺功能的影响[J]. 临床医药文献电子杂志, 2016, 3(11): 2197-2197, 2200.</mixed-citation></ref><ref id="hanspub.43892-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">蒋红宇, 邱根祥, 宋海萍. 氧驱雾化吸入普米克令舒治疗小儿哮喘急性发作疗效及对肺功能的影响[J]. 实用药物与临床, 2014, 17(1): 103-105.</mixed-citation></ref></ref-list></back></article>